- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting | 446 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): AGMEGM
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
03.06.2026 / 06:45 CET/CEST
MindMaze... ► Artikel lesen | |
| Di | MindMaze Therapeutics verkauft Non-Core-Asset und senkt Kosten um ein Drittel | 14 | Investing.com Deutsch | ||
| MINDMAZE THERAPEUTICS HOLDING SA ADR Aktie jetzt für 0€ handeln | |||||
| Di | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification | 1.466 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
02-Jun-2026 / 06:45 CET/CEST
Release... ► Artikel lesen | |
| 26.05. | Mindmaze sichert sich 8 Millionen Franken | 24 | cash | ||
| 26.05. | MindMaze Therapeutics: CHF 8,0 Mio. strategische Eigenkapitalfinanzierung | 17 | Investing.com Deutsch | ||
| 26.05. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing | 1.489 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Financing
MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
26-May-2026 / 06:50 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.05. | MindMaze Therapeutics: Partnerschaft mit Vibra Healthcare für US-Expansion | 27 | Investing.com Deutsch | ||
| 12.05. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S. | 1.499 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Partnership
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across... ► Artikel lesen | |
| 30.04. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S. | 496 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Partnership
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision... ► Artikel lesen | |
| 15.04. | MindMaze: Jahresbericht 2025 veröffentlicht - Verlust CHF 9,9 Mio. | 42 | Investing.com Deutsch | ||
| 15.04. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update | 2.933 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Annual Results
MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update
15-Apr-2026 / 07:00 CET/CEST
Release of an ad hoc... ► Artikel lesen | |
| 07.04. | Edison Group: Edison Issues Report on MindMaze Therapeutics (MMTX) | 572 | Newsfile | London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a commercial-stage health technology company pioneering... ► Artikel lesen | |
| 31.03. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation | 862 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study results
MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation... ► Artikel lesen | |
| 19.03. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank | 699 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
19.03.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| 12.03. | MindMaze Therapeutics Holding Names Zach Henderson CEO | 23 | RTTNews | ||
| 12.03. | MindMaze ernennt Zach Henderson zum neuen CEO | 14 | Investing.com Deutsch | ||
| 12.03. | MindMaze names Zach Henderson as chief executive officer | 7 | Investing.com | ||
| 12.03. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale | 1.596 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Personnel
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
12-March-2026 / 07:00... ► Artikel lesen | |
| 03.03. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation | 1.406 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
03-March-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 23.12.25 | MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics | 637 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
23.12.2025... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,019 | +22,58 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures | Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MINDMAZE THERAPEUTICS HOLDING SA ADR gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINDMAZE THERAPEUTICS HOLDING SA ADR finden Sie auf Wallstreet Online.